Reducing Cannabis Use in Young Adults With Psychosis Using iCanChange, a Mobile Health App: Protocol for a Pilot Randomized Controlled Trial (ReCAP-iCC)

Abstract

Background Cannabis use is the most prevalent among adolescents and young adults; frequent consumption is associated with cannabis use disorder (CUD) and psychosis, with a high prevalence (up to 50%) of CUD in individuals with first-episode psychosis (FEP). Early Intervention Services (EIS) for psychosis include face-to-face psychosocial interventions for CUD, because reducing or discontinuing cannabis use improves clinical and health care service use outcomes. However, multiple barriers (eg, staff availability and limited access to treatment) can hinder the implementation of these interventions. Mobile health (mHealth) interventions may help circumvent some of these barriers; however, to date, no study has evaluated the effects of mHealth psychological interventions for CUD in individuals with FEP. Objective This study describes the protocol for a pilot randomized controlled trial using a novel mHealth psychological intervention (iCanChange [iCC]) to address CUD in young adults with FEP. iCC was developed based on clinical evidence showing that in individuals without psychosis, integrating the principles of cognitive behavioral therapy, motivational interviewing, and behavioral self-management approaches are effective in improving cannabis use–related outcomes. Methods Consenting individuals (n=100) meeting the inclusion criteria (eg, aged 18-35 years with FEP and CUD) will be randomly allocated in a 1:1 ratio to the intervention (iCC+modified EIS) or control (EIS) group. The iCC is fully automatized and contains 21 modules that are completed over a 12-week period and 3 booster modules available during the 3-month follow-up period. Validated self-report measures will be taken via in-person assessments at baseline and at 6, 12 (end point), and 24 weeks (end of trial); iCC use data will be collected directly from the mobile app. Primary outcomes are intervention completion and trial retention rates, and secondary outcomes are cannabis use quantity, participant satisfaction, app use, and trial recruiting parameters. Exploratory outcomes include severity of psychotic symptoms and CUD severity. For primary outcomes, we will use the chi-square test using data collected at week 12. We will consider participation in iCC acceptable if ≥50% of the participants complete at least 11 out of 21 intervention modules and the trial feasible if attrition does not reach 50%. We will use analysis of covariance and mixed-effects models for secondary outcomes and generalized estimating equation multivariable analyses for exploratory outcomes. Results Recruitment began in July 2022, and data collection is anticipated to be completed in July 2024. The main results are expected to be submitted for publication in 2024. We will engage patient partners and other stakeholders in creating a multifaceted knowledge translation plan to reach a diverse audience. Conclusions If feasible, this study will provide essential data for a larger-scale efficacy trial of iCC on cannabis use outcomes in individuals with FEP and CUD. Trial Registration ClinicalTrials.gov NCT05310981; https://www.clinicaltrials.gov/ct2/show/NCT05310981 International Registered Report Identifier (IRRID) PRR1-10.2196/40817

A Mobile Health App (ChillTime) Promoting Emotion Regulation in Dual Disorders: Acceptability and Feasibility Pilot Study

“…These results are consistent with results reported in similar studies with cannabis [68] and cannabis users who had a recent psychotic episode [69]. These results are also consistent with the expected completion rate in a population with dual disorder (with cannabis use) [70]. A larger study may allow us to replicate this usage pattern and see whether it is associated with certain patient characteristics.…”

Mobile Intervention to Address Cannabis Use Disorder Among Black Adults: Protocol for a Randomized Controlled Trial

“…Though extant literature has highlighted existing mHealth work for cannabis use and CUD [ 32 ], including mHealth interventions tailored to treat specific populations (ie, individuals with psychosis and comorbid substance use) [ 33 , 34 ], this study is the first to target specific psycho-sociocultural factors related to cannabis use and use-related problems among Black cannabis users through a mobile intervention. Should the CT-MICART app prove efficacious in reducing cannabis use, it will provide health care officials and researchers a unique opportunity to further refine and provide low-cost and easily accessible treatment for a historically underrepresented and underserved population.…”

“…Extant literature has highlighted existing mHealth work for cannabis use and CUD [ 32 ], including mHealth interventions that have been culturally tailored to treat specific populations such as individuals with psychosis [ 33 ], as well as individuals with comorbid CUD and cigarette smoking [ 34 ]. However, no mHealth interventions for cannabis use and CUD currently target specific psycho-sociocultural factors related to cannabis use and use-related problems among Black individuals who use cannabis with probable CUD.…”

Exploring Digital-based Therapies for Adolescents with Substance Use Disorders: A Brief Literature Review

“…4,5 While in person interventions are the gold-standard, access to these treatments is limited by affordability, scarcity of trained staff, availability of services, and physical access to treatment. 6 One of the most beneficial aspects of smartphone technology is the ability to provide immediate, "justin-time alerts" to prevent patients from using substances. 7 These alerts can be employed in a variety of situations, such as parties, when adolescents are at the highest risk of substance use.…”